1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Financials
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  05/16 04:00:00 pm EDT
136.26 USD   -1.20%
05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A)
AQ
05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/13KHF Welcomes the African Medicines Agency Treaty Cabinet Approval
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 6 51841 340102 97654 855--
Enterprise Value (EV)1 5 54836 84292 84836 33332 19229 618
P/E ratio -12,6x-53,3x8,98x5,08x17,5x39,7x
Yield ------
Capitalization / Revenue 108x51,5x5,58x2,49x5,55x7,78x
EV / Revenue 92,1x45,9x5,03x1,65x3,26x4,20x
EV / EBITDA -10,8x-50,3x6,86x2,65x7,55x9,62x
Price to Book 6,14x16,3x7,24x2,19x1,83x1,66x
Nbr of stocks (in thousands) 333 250395 710405 450397 760--
Reference price (USD) 19,6104254138138138
Announcement Date 02/26/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 60,280318 47122 0229 8857 046
EBITDA1 -515-73213 52813 7134 2633 080
Operating profit (EBIT)1 -546-76313 29613 6474 2331 770
Operating Margin -906%-95,0%72,0%62,0%42,8%25,1%
Pre-Tax Profit (EBT)1 -515-74513 28513 6104 2021 576
Net income1 -514-74712 20211 4743 3511 554
Net margin -854%-93,0%66,1%52,1%33,9%22,0%
EPS2 -1,55-1,9628,327,27,893,47
Dividend per Share2 ------
Announcement Date 02/26/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 4 9697 2116 0664 1055 9326 128
EBITDA -5 488----
Operating profit (EBIT)1 3 5585 4104 2272 2263 5903 616
Operating Margin 71,6%75,0%69,7%54,2%60,5%59,0%
Pre-Tax Profit (EBT)1 3 5525 4104 2292 1503 7293 680
Net income1 3 3334 8683 6571 9142 9982 865
Net margin 67,1%67,5%60,3%46,6%50,5%46,8%
EPS2 7,7011,38,584,767,136,67
Dividend per Share ------
Announcement Date 11/04/202102/24/202205/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 9714 49810 12818 52222 66325 237
Leverage (Debt / EBITDA) 1,89x6,15x-0,75x-1,35x-5,32x-8,19x
Free Cash Flow1 -4911 96013 3368 5014 8162 573
ROE (Net Profit / Equities) -38,0%-40,0%146%58,4%10,9%3,79%
Shareholders' equity1 1 3531 8688 35319 63130 69740 987
ROA (Net Profit / Asset) -28,9%-16,7%76,2%40,4%6,29%0,83%
Assets1 1 7764 46316 00328 39353 305187 800
Book Value Per Share2 3,196,4235,163,175,383,1
Cash Flow per Share2 -5,3231,619,96,601,36
Capex1 31,667,4284703478396
Capex / Sales 52,4%8,40%1,54%3,19%4,83%5,63%
Announcement Date 02/26/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 54 855 014 989
Net sales (USD) 18 471 000 000
Number of employees 2 700
Sales / Employee (USD) 6 841 111
Free-Float 90,6%
Free-Float capitalization (USD) 49 679 895 488
Avg. Exchange 20 sessions (USD) 923 330 319
Average Daily Capital Traded 1,68%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA